Formulation and Evaluation of Ocular Inserts Containing Berberine HCL and Curcumin
Abstract
Objective: The purpose of this work was to develop an ocular insert for the treatment of allergic conjunctivitis.
Methods: Nine formulations of ocular inserts were prepared by solvent casting method using different ratios of various well-known hydrophilic polymers such as Hydroxy Propyl Methyl Cellulose (HPMC), Poly Vinyl Alcohol (PVA), Pluronic F-68, Glycerine as a plasticizer, benzylkonium chloride as a preservative and distilled water as a solvent. These formulations were evaluated for mechanical properties like tensile strength, folding endurance. The physicochemical properties like surface pH, drug content, thickness, weight variation, percent moisture absorption was also evaluated.
Results: Based on the evaluation, it was found that formulation F9 was highest tensile strength and lowest folding endurance. Formulation F8 posess highest folding endurance as well as good tensile strength.
Conclusion: Based on results, it was selected as the optimized formulation.
Keywords: Curcumin, Berberine Hcl, HPMC, PVA, Pluronic F-68, Glycerine.
Keywords:
Curcumin, Berberine Hcl, HPMC, PVA, Pluronic F-68, GlycerineDOI
https://doi.org/10.22270/jddt.v15i5.7117References
1. Gurtler F and Gurny R. Patent literature review of ophthalmic inserts. Drug Dev Ind Pharm. 1995; 21:1-18. https://doi.org/10.3109/03639049509048094
2. Chien YW. Novel drug delivery systems. Marcel Dekker, New York. 1991;2 ^ Edn:269-300. https://doi.org/10.1201/9780367805456
3. Khar RK and Vyas SP. Targeted and controlled drug delivery novel carrier systems. CBS Publishers and Distributors, New Delhi. 2002;384-389.
4. Patel JM, Shah KK and Patel MM. Formulation and evaluation of temperature dependant ophthalmic gel solution of Brimonidine tartrate. IJPCS. 2012;1:1190-1199.
5. Gevariya H,Dharmasi A,Girhepunje A and Pal R. Once a day ocular inserts for sustained delivery of Levofl oxacin: design, formulation and evaluation. Asian J Pharm. 2009;3:314-318. https://doi.org/10.4103/0973-8398.59954
6. SultanaY,Aqui1 M andAli, A.Ocular inserts for controlled delivery of pefloxacinmesylate: preparation and evaluation. Acta Pharm. 2005;55:305-314
7. Murthy SN and Hiremath SR. Biodegradable polymers matrix based Ocuserts. Int J Pharm Excip. 2002;34- 37.
8. Ahad HA, Sreeramulu J, Padmaja BS, Reddy MN and Guruprakash P. Preparation of fluconazole b- cyclodextrin complex ocuserts: invitro and invivo evaluation. ISRN Pharm. 2002; 2011: 1-8. https://doi.org/10.5402/2011/237501 PMid:22389846 PMCid:PMC3263730
9. Dave V,Yadav S, Paliwal S, Sharma S and Kumar D. Design and evaluation of accelofenac ocular insert with special ref to cataracts and conjunctivitis. JCPS. 2013;22:449-455. https://doi.org/10.5246/jcps.2013.05.066
10. Patel DH, Patel MP and Patel MM. Formulation and evaluation of drug free ophthalmic inserts prepared by various synthetic polymers. J Young Pharm. 2013;1:116-120. https://doi.org/10.4103/0975-1483.55742
11. Attiashafie MA and Hassanrady MA. In vitro and in vivo evaluation of timolol maleate ocular inserts using different polymers. J Clin Exp Ophthalmol. 2013;3:24.
12. Indian Pharmacopoeia. Ministry of Health and Family welfare. Government of India. Controller of Publication, New Delhi. 1996;2:117-147.
13. Michael HA, Mostafa H, Mehdi J and Taravat G. Draize rabbit eye test compatibility with eye irritation threshold in humans: a quantitative structural-activity relationship analysis. Toxicol Sci. 2003;76:384-391. https://doi.org/10.1093/toxsci/kfg242 PMid:14514959
14. Geethalakshmi A, Karki R, Sagi P, Jha SK and Venkatesh DP. Temperature triggered in situ gelling system for Betoxolol in glaucoma. J Appl Pharm Sci. 2013;3:153-159. https://doi.org/10.7324/JAPS.2013.30227
15. Podkociel na B, Bartnicki A and Gawdzik B. New crosslinked hydrogels derivatives of 2-hydroxyethyl methacrylate: Synthesis, modifications and properties. express Polymer Letters 2012;6:759-771. https://doi.org/10.3144/expresspolymlett.2012.81
16. Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts-Advancement in therapy of eye diseases. Journal of advanced pharmaceutical technology & research. 2010 Jul 1;1(3):291-296. https://doi.org/10.4103/0110-5558.72419 PMid:22247860 PMCid:PMC3255407
Published
Abstract Display: 1174 
PDF Downloads: 1378 PDF Downloads: 71 How to Cite
Issue
Section
Copyright (c) 2025 Vaibhav Rathore , Suresh Kumar Dev , Garima Joshi , Pratim Kumar Choudhury
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.